Meridian Radiopharmaceuticals is developing what we believe could be the first curative therapy for a large subset of stage IV breast cancer patients.

Our approach builds on a widely used bone drug with decades of safe clinical use and billions in sales. By swapping one atom for a radioactive isotope, we add a targeted therapeutic effect without changing the drug’s chemistry. This lets us pursue the FDA’s 505(b)(2) pathway and seek Breakthrough Therapy designation, accelerating and de-risking development. We’ve partnered with UT Austin, secured DOE research funding, and are preparing our INTERACT package for the FDA. We’re presently looking for a few more investors to close out our pre-seed to fund first in-animal studies.